Represented Oklahoma Medical Research Foundation (OMRF) in a suit against Eli Lilly in the Western District of Oklahoma. OMRF alleged patent infringement and breach of a license agreement in connection with Eli Lilly's sales of Xigris, the first FDA-approved drug to treat severe sepsis. The suit settled on the eve of trial after more than 60 depositions, production of more than one million pages of documents by Eli Lilly, and a Markman hearing resulting in a claim construction favorable to our client.

Oklahoma Med. Research Found. v. Eli Lilly & Co., No. 01-0456 (W.D. Okla. filed Mar. 15, 2001).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Sale of interest in a physician owned cath lab for Atlanta Cardiology Group P.C.
Represented Atlanta Cardiology Group P.C. in the sale of majority interest in a physician owned cath lab to more
Copyright infringement litigation defense for one of the world's leading music companies
Represented one of the world's leading music companies in copyright infringement litigation. Summary judgment was granted in favor of our more
Environmental litigation for a major bottled water company
Briefed and argued on behalf of a major bottle water company in a case involving a challenge under Michigan’s common law of groundwater, state more
Lee Valley Tools Ltd., et al. v. Sears, Roebuck & Co., et al.
Successfully represented Lee Valley Tools Ltd. in obtaining a U.S. patent and patent re-issuance for a power tool accessory, and successfully more